A new antiviral compound that blocks Ebola’s ability to replicate has been found to provide complete protection to monkeys against the deadly virus when treated three days after infection, scientists say.
The findings suggest that the compound, known as GS-5734, should be further developed as a potential treatment.
Researchers from US Army Medical Research Institute of Infectious Diseases (USAMRIID) used cell culture and animal models to demonstrate the compound’s antiviral activity against several pathogens, including Ebola virus.
In animal studies, treatment initiated on day 3 post-infection with Ebola virus resulted in 100% survival of the rhesus monkeys.
The animals also exhibited a substantial reduction in viral load and a marked decrease in the physical signs of disease, researchers said. Read more